Ardelyx (ARDX) Stock Forecast, Price Target & Predictions
ARDX Stock Forecast
Ardelyx stock forecast is as follows: an average price target of $8.75 (represents a 64.78% upside from ARDX’s last price of $5.31) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
ARDX Price Target
ARDX Analyst Ratings
Buy
Ardelyx Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Aug 05, 2024 | Ed Arce | H.C. Wainwright | - | - | 81.82% | 107.16% |
Jul 05, 2024 | Ed Arce | H.C. Wainwright | - | - | 89.04% | 88.32% |
May 24, 2024 | Christopher Raymond | Raymond James | - | - | 108.31% | 182.49% |
Dec 18, 2023 | Ryan Deschner | Raymond James | - | - | 90.33% | 125.99% |
Dec 30, 2022 | Citigroup | - | - | 145.61% | 31.83% | |
Dec 29, 2022 | Laura Chico | Wedbush | - | - | -14.35% | -62.34% |
10
Ardelyx Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 4 |
Avg Price Target | - | - | $12.00 |
Last Closing Price | $5.31 | $5.31 | $5.31 |
Upside/Downside | -100.00% | -100.00% | 125.99% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Aug 05, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Aug 02, 2024 | Wedbush | Buy | Buy | Hold |
Jul 05, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Jul 02, 2024 | Piper Sandler | Overweight | Neutral | Downgrade |
Jun 20, 2024 | Wedbush | Buy | Buy | Hold |
May 24, 2024 | Piper Sandler | Overweight | Overweight | Hold |
May 24, 2024 | Wedbush | Buy | Buy | Hold |
May 03, 2024 | Cowen & Co. | Buy | Buy | Hold |
May 03, 2024 | Citigroup | Buy | Buy | Hold |
Apr 05, 2024 | Wedbush | Buy | Buy | Hold |
10
Ardelyx Financial Forecast
Ardelyx Revenue Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $56.39M | $22.33M | $11.37M | $44.18M | $4.99M | $2.53M | $468.00K | $1.03M | $1.17M | $1.31M | $6.58M | $1.81M | $2.71M | $1.84M | $1.21M | $2.25M | $3.01M |
Avg Forecast | $181.50M | $172.00M | $164.50M | $157.00M | $110.73M | $101.97M | $93.02M | $83.32M | $108.56M | $86.64M | $55.03M | $36.40M | $34.06M | $22.57M | $15.28M | $10.41M | $23.18M | $3.92M | $2.22M | $875.00K | $875.50K | $1.32M | $940.00K | $1.38M | $1.66M | $1.36M | $1.81M | $550.00K | $975.00K | $150.00K |
High Forecast | $233.86M | $221.62M | $211.96M | $202.29M | $142.68M | $131.38M | $119.86M | $123.96M | $125.56M | $86.84M | $55.03M | $36.40M | $37.65M | $24.09M | $19.69M | $13.41M | $29.86M | $3.92M | $2.22M | $875.00K | $875.50K | $1.32M | $940.00K | $1.38M | $1.66M | $1.36M | $1.81M | $550.00K | $975.00K | $150.00K |
Low Forecast | $153.57M | $145.53M | $139.19M | $132.84M | $93.69M | $86.28M | $78.71M | $65.50M | $98.26M | $86.44M | $55.03M | $36.40M | $32.16M | $20.81M | $12.93M | $8.80M | $19.61M | $3.92M | $2.22M | $875.00K | $875.50K | $1.32M | $940.00K | $1.38M | $1.66M | $1.36M | $1.81M | $550.00K | $975.00K | $150.00K |
# Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 8 | 4 | 4 | 4 | 5 | 7 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 6 | 8 | 8 | 9 | 12 | 7 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.50% | 1.46% | 1.09% | 1.91% | 1.27% | 1.14% | 0.53% | 1.18% | 0.89% | 1.40% | 4.79% | 1.09% | 2.00% | 1.01% | 2.21% | 2.31% | 20.09% |
Forecast
Ardelyx EBITDA Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 8 | 4 | 4 | 4 | 5 | 7 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 6 | 8 | 8 | 9 | 12 | 7 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $7.40M | $-16.62M | $-24.76M | $12.52M | $-20.55M | $-25.97M | $-27.09M | $-35.06M | $-41.91M | $-43.62M | $-31.63M | $-27.14M | $-16.47M | $-23.26M | $-20.52M | $-17.88M | $-21.16M |
Avg Forecast | $-161.35M | $-152.90M | $-146.23M | $-139.57M | $-98.43M | $-90.64M | $-82.69M | $-74.07M | $-96.51M | $-77.02M | $-48.92M | $-45.32M | $-30.28M | $-20.06M | $-13.58M | $-35.83M | $-37.28M | $-3.49M | $-1.97M | $-28.32M | $-778.28K | $-1.17M | $-835.62K | $-30.67M | $-1.48M | $-1.21M | $-1.61M | $-20.52M | $-866.73K | $-133.34K |
High Forecast | $-136.52M | $-129.37M | $-123.73M | $-118.09M | $-83.29M | $-76.70M | $-69.97M | $-58.23M | $-87.35M | $-76.84M | $-48.92M | $-36.26M | $-28.59M | $-18.50M | $-11.49M | $-28.66M | $-29.82M | $-3.49M | $-1.97M | $-22.66M | $-778.28K | $-1.17M | $-835.62K | $-24.54M | $-1.48M | $-1.21M | $-1.61M | $-16.42M | $-866.73K | $-133.34K |
Low Forecast | $-207.89M | $-197.01M | $-188.42M | $-179.83M | $-126.83M | $-116.79M | $-106.55M | $-110.19M | $-111.62M | $-77.20M | $-48.92M | $-54.39M | $-33.47M | $-21.41M | $-17.50M | $-42.99M | $-44.73M | $-3.49M | $-1.97M | $-33.99M | $-778.28K | $-1.17M | $-835.62K | $-36.81M | $-1.48M | $-1.21M | $-1.61M | $-24.63M | $-866.73K | $-133.34K |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.37% | 1.22% | 0.69% | -0.34% | 5.89% | 13.15% | 0.96% | 45.04% | 35.79% | 52.20% | 1.03% | 18.36% | 13.63% | 14.47% | 1.00% | 20.63% | 158.65% |
Forecast
Ardelyx Net Income Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 8 | 4 | 4 | 4 | 5 | 7 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 6 | 8 | 8 | 9 | 12 | 7 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $6.63M | $-17.12M | $-26.77M | $10.70M | $-23.91M | $-26.94M | $-28.07M | $-37.22M | $-43.59M | $-45.19M | $-33.16M | $-28.88M | $-18.11M | $-24.96M | $-22.37M | $-19.79M | $-23.54M |
Avg Forecast | $49.54M | $42.46M | $37.75M | $33.03M | $4.13M | $-2.77M | $-9.19M | $-18.83M | $1.25M | $-11.57M | $-25.01M | $-46.96M | $-22.34M | $-25.38M | $-27.20M | $-37.12M | $-38.53M | $-39.50M | $-45.18M | $-29.35M | $-71.26M | $-82.42M | $-85.71M | $-32.15M | $-61.28M | $-66.32M | $-62.75M | $-22.37M | $-76.20M | $-86.79M |
High Forecast | $68.12M | $58.39M | $51.90M | $45.42M | $5.67M | $-2.22M | $-7.35M | $-9.16M | $4.99M | $-9.25M | $-20.01M | $-37.57M | $-9.93M | $-13.84M | $-21.76M | $-29.70M | $-30.82M | $-39.50M | $-45.18M | $-23.48M | $-71.26M | $-82.42M | $-85.71M | $-25.72M | $-61.28M | $-66.32M | $-62.75M | $-17.90M | $-76.20M | $-86.79M |
Low Forecast | $39.63M | $33.97M | $30.19M | $26.42M | $3.30M | $-3.81M | $-12.64M | $-24.42M | $-4.99M | $-15.91M | $-34.39M | $-56.35M | $-27.30M | $-34.61M | $-37.40M | $-44.55M | $-46.23M | $-39.50M | $-45.18M | $-35.22M | $-71.26M | $-82.42M | $-85.71M | $-38.58M | $-61.28M | $-66.32M | $-62.75M | $-26.85M | $-76.20M | $-86.79M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.26% | 0.63% | 0.72% | -0.28% | 0.61% | 0.60% | 0.96% | 0.52% | 0.53% | 0.53% | 1.03% | 0.47% | 0.27% | 0.40% | 1.00% | 0.26% | 0.27% |
Forecast
Ardelyx SG&A Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 8 | 4 | 4 | 4 | 5 | 7 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 6 | 8 | 8 | 9 | 12 | 7 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $32.66M | $27.19M | $26.80M | $19.73M | $18.67M | $18.86M | $19.34M | $15.33M | $19.71M | $20.12M | $17.13M | $11.34M | $7.63M | $7.04M | $7.14M | $6.86M | $6.92M |
Avg Forecast | $678.21M | $642.71M | $614.69M | $586.66M | $413.76M | $381.02M | $347.59M | $311.34M | $405.66M | $323.76M | $205.63M | $32.35M | $127.27M | $84.33M | $57.10M | $38.88M | $16.31M | $14.65M | $8.30M | $3.27M | $3.27M | $4.92M | $3.51M | $5.14M | $6.21M | $5.08M | $6.76M | $2.06M | $3.64M | $560.50K |
High Forecast | $873.87M | $828.13M | $792.02M | $755.91M | $533.13M | $490.94M | $447.88M | $463.18M | $469.18M | $324.50M | $205.63M | $38.82M | $140.70M | $90.00M | $73.58M | $50.10M | $19.57M | $14.65M | $8.30M | $3.27M | $3.27M | $4.92M | $3.51M | $5.14M | $6.21M | $5.08M | $6.76M | $2.06M | $3.64M | $560.50K |
Low Forecast | $573.85M | $543.81M | $520.10M | $496.39M | $350.10M | $322.39M | $294.11M | $244.75M | $367.16M | $323.01M | $205.63M | $25.88M | $120.17M | $77.78M | $48.32M | $32.90M | $13.04M | $14.65M | $8.30M | $3.27M | $3.27M | $4.92M | $3.51M | $5.14M | $6.21M | $5.08M | $6.76M | $2.06M | $3.64M | $560.50K |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.39% | 0.48% | 0.69% | 1.21% | 1.27% | 2.27% | 5.91% | 4.69% | 4.01% | 5.73% | 3.33% | 1.83% | 1.50% | 1.04% | 3.47% | 1.88% | 12.35% |
Forecast
Ardelyx EPS Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 8 | 4 | 4 | 4 | 5 | 7 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 6 | 8 | 8 | 9 | 12 | 7 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.03 | $-0.00 | $-0.13 | $0.06 | $-0.14 | $-0.19 | $-0.21 | $-0.32 | $-0.42 | $-0.45 | $-0.34 | $-0.32 | $-0.20 | $-0.28 | $-0.25 | $-0.27 | $-0.37 |
Avg Forecast | $0.21 | $0.18 | $0.16 | $0.14 | $0.02 | $-0.01 | $-0.04 | $-0.08 | $0.01 | $-0.05 | $-0.11 | $-0.15 | $-0.09 | $-0.11 | $-0.12 | $-0.10 | - | $-0.17 | $-0.19 | $-0.22 | $-0.30 | $-0.35 | $-0.37 | $-0.33 | $-0.26 | $-0.28 | $-0.27 | $-0.25 | $-0.32 | $-0.37 |
High Forecast | $0.29 | $0.25 | $0.22 | $0.19 | $0.02 | $-0.01 | $-0.03 | $-0.04 | $0.02 | $-0.04 | $-0.08 | $-0.12 | $-0.04 | $-0.06 | $-0.09 | $-0.08 | - | $-0.17 | $-0.19 | $-0.22 | $-0.30 | $-0.35 | $-0.37 | $-0.33 | $-0.26 | $-0.28 | $-0.27 | $-0.25 | $-0.32 | $-0.37 |
Low Forecast | $0.17 | $0.14 | $0.13 | $0.11 | $0.01 | $-0.02 | $-0.05 | $-0.10 | $-0.02 | $-0.07 | $-0.15 | $-0.20 | $-0.12 | $-0.15 | $-0.16 | $-0.14 | - | $-0.17 | $-0.19 | $-0.22 | $-0.30 | $-0.35 | $-0.37 | $-0.33 | $-0.26 | $-0.28 | $-0.27 | $-0.25 | $-0.32 | $-0.37 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.28% | 0.00% | 1.29% | 25.92% | 0.83% | 0.99% | 0.95% | 1.05% | 1.20% | 1.23% | 1.03% | 1.22% | 0.71% | 1.05% | 1.00% | 0.83% | 1.00% |
Forecast
Ardelyx Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
HEPA | Hepion Pharmaceuticals | - | - | 10506.06% | Buy |
LXRX | Lexicon Pharmaceuticals | - | - | 597.67% | Buy |
INZY | Inozyme Pharma | - | - | 422.06% | Buy |
PDSB | PDS Bio | - | - | 330.62% | Buy |
ZURA | Zura Bio | - | - | 266.30% | Buy |
TERN | Terns Pharmaceuticals | - | - | 146.11% | Buy |
VSTM | Verastem | - | - | 108.25% | Buy |
MREO | Mereo BioPharma Group | - | - | 81.45% | Buy |
ARDX | Ardelyx | - | - | 64.78% | Buy |
MCRB | Seres Therapeutics | - | - | 62.34% | Buy |
IBRX | ImmunityBio | - | - | 56.86% | Buy |
HOOK | HOOKIPA Pharma | - | - | 39.53% | Buy |